2. Клинические рекомендации. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 154. Доступ: https://cr.minzdrav.gov.ru/schema/154_3 (дата обращения – 01.03.2024).

3. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–60. https://doi.org/10.1093/eurheartj/ehx419. PMID: 29045581.

4. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–60. https://doi.org/10.1016/S0140-6736(09)60503-1. PMID: 19482214. PMCID: PMC2715005.

5. Steg P.G., James S., Harrington R.A. et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010; 122(21): 2131–41. https://doi.org/10.1161/CIRCULATIONAHA.109.927582. PMID: 21060072.

6. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–57. https://doi.org/10.1056/NEJMoa0904327. PMID: 19717846.

7. Montalescot G., Wiviott S.D., Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet. 2009; 373(9665): 723–31. https://doi.org/10.1016/S0140-6736(09)60441-4. PMID: 19249633.

8. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001–15. https://doi.org/10.1056/NEJMoa0706482. PMID: 17982182.

9. Mehta S.R., Tanguay J.F., Eikelboom J.W. et al.; for CURRENT-OASIS Trial Investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010; 376(9748): 1233–43. https://doi.org/10.1016/S0140-6736(10)61088-4. PMID: 20817281.

10. Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001; 358(9281): 527–33. https://doi.org/10.1016/s0140-6736(01)05701-4. PMID: 11520521.

11. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls. rosminzdrav.ru/GRLS.aspx?RegNumber=&MnnR=ацетилсалициловая+кислота%2bКлопидог рел&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&regtype=1%2c6& pageSize=10&order=Registered&orderType=desc&pageNum=1 (дата обращения – 01.03.2024).

12. Mega J.L., Braunwald E., Wiviott S.D. et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19. https://doi.org/10.1056/NEJMoa1112277. PMID: 22077192.

13. Bonaca M.P., Bhatt D.L., Cohen M. et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–800. https://doi.org/10.1056/NEJMoa1500857. PMID: 25773268.

14. Bonaca M.P., Bhatt D.L., Steg P.G. et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J. 2016; 37(14): 1133–42. https://doi.org/10.1093/eurheartj/ehv531. PMID: 26491109.

15. Costa F., Van Klaveren D., Feres F. et al.; PRECISE-DAPT Study Investigators. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019; 73(7): 741–54.https://doi.org/10.1016/j.jacc.2018.11.048. PMID: 30784667.

16. Lopes R.D., Heizer G., Aronson R. et al.; for the AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. NEJM. 2019; 380(16): 1509–24. https://doi.org/10.1056/NEJMoa1817083. PMID: 30883055.

17. Cannon C.P., Bhatt D.L., Oldgren J. et al.; RE-DUAL Steering Committee PCI and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377(16): 1513–24. https://doi.org/10.1056/NEJMoa1708454. PMID: 28844193.

18. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375(25): 2423–34. https://doi.org/10.1056/NEJMoa1611594. PMID: 27959713.

19. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998; 97(22): 2202–12. https://doi.org/10.1161/01.cir.97.22.2202. PMID: 9631869.

20. Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation. 1997; 95(12): 2643–51. https://doi.org/10.1161/01.cir.95.12.2643. PMID: 9193433.

21. Pitt B., Remme W., Zannad F. et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309–21. https://doi.org/10.1056/NEJMoa030207. PMID: 12668699.

22. McMurray J.J., Packer M., Desai A.S. et al; on behalf of the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004. https://doi.org/10.1056/NEJMoa1409077. PMID: 25176015.

23. Beltrame J.F., Crea F., Kaski J.C. et al.; Coronary Vasomotion Disorders International Study Group (COVADIS). The who, what, why, when, how and where of vasospastic angina. Circ J. 2016; 80(2): 289–98. https://doi.org/10.1253/circj.CJ-15-1202. PMID: 26686994.

24. Han X., Zhang Y., Yin L. et al. Statin in the treatment of patients with myocardial infarction: A meta-analysis. Medicine (Baltimore). 2018; 97(12): e0167. https://doi.org/10.1097/ MD.0000000000010167. PMID: 29561426. PMCID: PMC5895306.

25. Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387–97. https://doi.org/10.1056/NEJMoa1410489. PMID: 26039521.

26. Sabatine M.S., Giugliano R.P., Keech A.C. et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376(18): 1713–22. https://doi.org/10.1056/NEJMoa1615664. PMID: 28304224.

27. Schwartz G.G., Steg G., Szarek M. et al.; for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379(22): 2097–107. https://doi.org/10.1056/NEJMoa1801174. PMID: 30403574.